The European Medicines Agency (EMA) has today published a new Direct Healthcare Professional Communication (DHPC) concerning Remsima (infliximab), an infliximab biosimilar widely used in immunology indications across Europe.[1] This DHPC represents a business‑critical regulatory update for pharmaceutical companies holding marketing authorisations for infliximab biosimilars, hospital procurement organisations, and manufacturers operating fill‑finish and secondary packaging lines for injectable biologics in the European Economic Area. A DHPC is a formal risk communication tool used by the EMA and national competent authorities to inform prescribers, pharmacists and other healthcare professionals of important new safety information or significant changes in the conditions of use of an authorised medicine. For industry stakeholders, the appearance of a DHPC immediately triggers internal impact assessment across regulatory, pharmacovigilance (PV), medical affairs, quality, supply chain and commercial teams, because it can affect product labelling, risk minimisation measures, educational materials, and inventory already in the distribution network.[1]

From a B2B pharmaceutical operations perspective, the DHPC for Remsima has several direct implications. First, regulatory affairs teams at the marketing authorisation holder (MAH) and its European affiliates will need to align the content of the DHPC with the latest product information, including the Summary of Product Characteristics (SmPC) and package leaflet, and ensure consistent implementation across all EU and EEA markets. This typically involves rapid coordination with national agencies for translation, approval and dissemination of the communication to prescribers and pharmacies. Second, pharmacovigilance units must update risk management plans (RMPs), signal detection activities and periodic safety update reports (PSURs) to reflect the new safety or use information highlighted in the DHPC.[1] These updates can influence ongoing and planned post‑authorisation safety studies and may require amendments to observational registries or risk minimisation programmes.

Manufacturing and quality operations in Europe will also need to evaluate whether the DHPC content necessitates any changes to packaging components, labelling or patient information leaflets used in current production campaigns for Remsima. For contract manufacturing organisations (CMOs) and contract packaging providers involved in sterile filling, lyophilisation, vial or pre‑filled syringe assembly, and secondary packaging of infliximab biosimilars, this may translate into artwork modifications, line changeovers, and updated quality checks to ensure that revised safety statements or instructions are correctly implemented. When a DHPC is linked to new contraindications, warnings, or restrictions of use, there can also be an operational impact on inventory already released to the market, potentially requiring relabelling, field corrections, or enhanced communication with hospital pharmacies and wholesalers to manage stock in a compliant manner.

For hospital procurement and tendering bodies across Europe, including centralised purchasing organisations and group purchasing organisations (GPOs), today’s DHPC is a signal to review ongoing and upcoming infliximab tenders in which Remsima and other biosimilars compete. Any change in the safety profile, patient selection criteria or monitoring requirements may affect product comparability assessments, pharmacoeconomic models, and risk‑sharing arrangements embedded into multi‑year framework agreements. Procurement leaders will need to liaise with clinical pharmacy and rheumatology, gastroenterology or dermatology departments to understand whether the DHPC changes daily practice, monitoring resources, or patient scheduling, and then feed this information back into contracting strategies and supply allocations.

From a broader strategic standpoint, the issuance of a DHPC for a high‑volume biosimilar like Remsima underscores the importance of robust pharmacovigilance infrastructure, data management and regulatory compliance in the European biosimilar market. Companies active in contract clinical trials, contract drug safety services and real‑world evidence generation can expect increased demand from MAHs seeking to strengthen their safety databases and post‑marketing evidence packages for infliximab and similar monoclonal antibodies. It also reinforces the need for digital solutions in safety signal management and regulatory submission workflows, such as integration with EMA systems for product and safety data, to allow rapid, auditable implementation of DHPC‑driven changes across multiple jurisdictions. For technology vendors providing laboratory information management systems (LIMS), safety databases, and quality document control platforms, this type of regulatory action can catalyse new projects focused on automation of label change control, DHPC tracking, and compliance dashboards for European biologics portfolios.

Finally, the Remsima DHPC aligns with a continuing trend in Europe toward tighter oversight of complex biologics, advanced therapies and biosimilars, with regulators using structured communications and networked data tools to manage product information lifecycles.[1] For senior executives overseeing European operations, this update highlights the importance of cross‑functional readiness: regulatory, PV, manufacturing, supply chain and commercial teams must be able to respond quickly and coherently to DHPCs to protect business continuity while maintaining full compliance. In competitive tenders and hospital contracts, companies that demonstrate agile implementation of EMA safety communications and transparent communication with clinical stakeholders can strengthen their position as reliable partners. In the medium term, the lessons learned from operationalising today’s DHPC for Remsima will inform internal playbooks for future regulatory communications across the company’s broader biologics and biosimilars pipeline in the European market.